Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Ellen M. Apperloo(Dialyse Centrum Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Secundino Cigarrán Guldris(Hospital Universitario Lucus Augusti), David Z.I. Cherney(University Health Network), Christoph Wanner(Universitätsklinikum Würzburg), Klaas Hoogenberg(Martini Ziekenhuis), José Luis Górriz(Universitat de València), Josep M. Cruzado, María Jesús Puchades(INCLIVA Health Research Institute), Roland E. Schmieder(Universitätsklinikum Erlangen), Annemarie van der Aart-van der Beek(Martini Ziekenhuis), Femke Waanders, Gozewijn D. Laverman(Ziekenhuis Groep Twente), André P. van Beek(University Medical Center Groningen), María José Soler(Mayo Clinic), Marina López-Martínez(Vall d'Hebron Institut de Recerca), Sofia B. Ahmed(University of Alberta), Jacobien C. Verhave(Rijnstate Hospital), Niels Jongs(University Medical Center Groningen)
Cited by 95
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k